FCM
ADMA icon

Fieldview Capital Management’s ADMA Biologics ADMA Stock Holding History

Fieldview Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-21,708
Closed -$396K – 477
2025
Q4 		$396K Buy
21,708
+1,486
+7% +$25K 0.07% 319
2025
Q3 		$296K Buy
+20,222
New +$347K 0.05% 333
2025
Q2 		– Sell
-130,623
Closed -$2.59M – 331
2025
Q1 		$2.59M Buy
+130,623
New +$2.26M 0.37% 105

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Fieldview Capital Management's ADMA Position: Q1 2026 in Review

Fieldview Capital Management sold out of ADMA Biologics (ADMA) in Q1 2026, closing a stake of 21,708 shares — an estimated $396K sold.

Fieldview Capital Management first reported a position in ADMA in Q1 2025 and held it in 3 quarters. The position peaked at $2.59M in Q1 2025. 357 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Fieldview Capital Management reported no remaining ADMA Biologics position as of Q1 2026 after selling out during the quarter.
  • Fieldview Capital Management sold 21,708 ADMA Biologics shares in Q1 2026, an estimated $396K.
  • Fieldview Capital Management first reported a position in ADMA Biologics in Q1 2025 and held it in 3 quarters.
  • Fieldview Capital Management's ADMA Biologics position peaked at $2.59M in Q1 2025.
  • 357 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Fieldview Capital Management's 13F filing for Q1 2026, filed 14 May 2026.